Business Context and Reporting Period
This Form 8-K, dated May 27, 2020, reports on AcelRx Pharmaceuticals, Inc. ("AcelRx") and its proposed acquisition of Tetraphase Pharmaceuticals, Inc. ("Tetraphase"). The filing details an amendment to the Merger Agreement originally executed on March 15, 2020, following a competing proposal from Melinta Therapeutics, Inc. The Tetraphase board has determined the Melinta proposal is not superior and recommends the amended merger.
Key Financial Metrics and Transaction Terms
The filing outlines the revised consideration for Tetraphase shareholders and specific financial thresholds for the transaction:
- Merger Consideration: Each Tetraphase share converts into:
- Cash: $0.2434 per share (subject to adjustment).
- Stock: 0.7217 shares of AcelRx common stock (subject to adjustment).
- Contingent Value Rights (CVRs): One CVR per share.
- Net Cash Adjustments:
- Cash consideration adjusts if Company Net Cash is less than $5,000,000 (up to $2,627,527).
- Exchange ratio adjusts if Company Net Cash is less than $2,372,473.
- Revised CVR Agreement: Total potential cash payout increased to $14.5 million (previously $12.5 million in stock and cash), contingent on XERAVA annual net sales milestones:
- $2.5 million for 2021 sales targets.
- $4.5 million for sales targets in any year through 2024.
- $7.5 million for sales targets in any year through 2024.
- Termination Fee: Increased from $810,000 to $1,441,000 payable by Tetraphase under specified circumstances.
Note: This filing does not provide AcelRx's or Tetraphase's standalone revenue, profit, cash flow, or debt metrics for the reporting period.
Material Changes Versus Prior Period
Compared to the original March 15, 2020 Merger Agreement, the following material changes were implemented:
- Consideration Structure: The CVR payout structure was revised to be entirely cash-based up to $14.5 million, replacing the previous mixed stock and cash structure.
- Termination Fee: The fee payable by Tetraphase was increased by approximately 78% (from $810,000 to $1,441,000).
- Voting Agreements: Amendments were executed with Tetraphase stockholders representing approximately 20% of voting power to support the merger and exchange warrants for cash and AcelRx stock.
Guidance, Outlook, Risks, and Contingencies
Outlook and Management Commentary: The Tetraphase board has approved the amended terms and rejected the Melinta Therapeutics proposal as non-superior. The transaction remains subject to shareholder approval and regulatory conditions.
Risks and Contingencies:
- Transaction Completion: Risks include failure to close the acquisition, inability to achieve expected synergies, or delays caused by competing bidders.
- Market Volatility: Fluctuations in AcelRx's stock price could impact the transaction.
- COVID-19 Impact: The ongoing pandemic may prolong or exacerbate operational and financial challenges.
- CVR Uncertainty: There is no assurance that XERAVA will achieve the net sales levels required to trigger CVR payments.
Investor Verification Checklist
- Verify the definitive proxy statement/prospectus (Form S-4 No. 333-237584) for complete terms and risk factors.
- Confirm the current "Company Net Cash" position to determine if the cash consideration or exchange ratio adjustments will be triggered.
- Review the specific annual net sales thresholds for XERAVA required to unlock the $14.5 million in CVR payments.
- Monitor the status of the competing proposal from Melinta Therapeutics, Inc.
- Check for updates on the impact of the COVID-19 pandemic on the closing timeline.